Company: Skills Alliance
Closing Date: 08 Mar 17
Salary (£): 40,000 - 60,000
A leading Biopharmaceutical Company are recruiting for a CRA position in Spain.This is an opportunity to join a world leading company that is expanding...
A leading Biopharmaceutical Company are recruiting for a CRA position in Spain.
This is an opportunity to join a world leading company that is expanding throughout Europe at the moment and will continue to do so over the next few years.
As they expand there will be excellent opportunities for progression and development. Their specialities include Oncology, Immunology, Cell-therapy and a range of other areas.
This would be outsourced via a CRO. In the CRA role you will be responsible for coordinating Phase I-IV clinical trials in Europe. This role offers excellent exposure to all therapeutic indication types and a defined career development. The responsibilities would include performing all site visits from feasibility to close out and it would be working on a regional basis. There is also the opportunity to take on lead CRA responsibilities. This is a great opportunity for an experienced CRA II or Senior CRA.
It is a full-time and permanent role offering around €40-50K + bonus + benefits. The position can be office-based or home-based across Spain.
Skills Alliance are the preferred supplier for this role. Please contact Yannick Dunkel for more details on 0044 20 3667 3964 or click apply now
Keywords: Senior CRA II / Senior CRA / Lead CRA / Oncology / Immunology / Project Manager / Pharma / Biotech / Cell therapy / Gene therapy / HIV / Hepatitis / Home based / CRO / Spain
10 Aldersgate Street, London
|Tel:||+44 20 7220 6200|
|Fax:||+44 870 831 1705|
|Website:||Visit Our Web Site|
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.